deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT03093402

JBT-101 in Systemic Lupus Erythematosus (SLE)

A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101 in Systemic Lupus Erythematosus

Sponsor: Autoimmunity Centers of Excellence

Conditions Lupus SLE Systemic Lupus Erythematosus
Interventions JBT-101 Placebo
Updated 23 times since 2017 Last updated: Oct 27, 2022 Started: Dec 21, 2017 Primary completion: Jul 28, 2021 Completion: Jul 28, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Lupus and SLE and is currently completed. Autoimmunity Centers of Excellence leads this study, which shows 23 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Jan 2018 · 7 months · monthly snapshot~Jan 2018 – ~May 2018 · 4 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~Dec 2018 · 2 months · monthly snapshot~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Nov 2019 · 7 months · monthly snapshot~Nov 2019 – ~Apr 2020 · 5 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Dec 2022 · 15 months · monthly snapshot~Dec 2022 – ~Jul 2024 · 19 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

23 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Dec 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. Sep 2021 — Dec 2022 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 18 earlier versions

  1. May 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE2

  3. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  4. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  5. Apr 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  6. Nov 2019 — Apr 2020 [monthly]

    Recruiting PHASE2

  7. Apr 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  8. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE2

  9. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE2

  10. Dec 2018 — Feb 2019 [monthly]

    Recruiting PHASE2

  11. Oct 2018 — Dec 2018 [monthly]

    Recruiting PHASE2

  12. Aug 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  13. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  14. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  15. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  16. Jan 2018 — May 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  17. Jun 2017 — Jan 2018 [monthly]

    Not Yet Recruiting PHASE2

  18. May 2017 — Jun 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Autoimmunity Centers of Excellence
  • Corbus Pharmaceuticals Inc.
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • Rho Federal Systems Division, Inc.
Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Charleston, United States , Cleveland, United States , Durham, United States , Hershey, United States , La Jolla, United States , Los Angeles, United States , Manhasset, United States , New Haven, United States , New York, United States and 4 more locations